Adjuvant Ginseng Use During Breast Cancer Drug Therapy

乳腺癌药物治疗期间辅助使用人参

• 批准号: 6873769
• 负责人: Laura Murphy
• 金额: $ 21.45万
• 依托单位: SOUTHERN ILLINOIS UNIVERSITY CARBONDALE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6873769
• 关键词: MCF7 cell; RNase protection assay; alternative medicine; apoptosis; athymic mouse; breast neoplasms; cell cycle; cell growth regulation; cell line; chemosensitizing agent; colorimetry; combination chemotherapy; cytotoxicity; drug interactions; drug screening /evaluation; enzyme linked immunosorbent assay; female; growth inhibitors; hormone therapy; immunocytochemistry; microarray technology; neoplasm /cancer chemotherapy; neoplastic growth; plant extracts; polymerase chain reaction; western blottings

DESCRIPTION (provided by applicant): Ginseng is an herb widely used by humans to treat lack of stamina, loss of appetite and cachexia, and impotence. In Asian medicine, ginseng is a common component in herbals used in treatment of cancer, including breast cancer. There is recent scientific evidence that ginseng and its ginsenoside components are effective in inhibiting breast cancer cell proliferation in vitro and tumor growth in vivo. Consequently, many patients may be taking ginseng supplements during treatment with standard chemotherapy and hormonal therapy regimens in an effort to enhance therapeutic results as well as ameliorate side effects of the cancer chemotherapeutic drugs. However, there is no information on how adjuvant ginseng use could influence the efficacy of the cancer therapeutic drugs. This R21 proposal will address the following questions. Will the adjuvant use of ginseng aid in or interfere with standard breast cancer chemo- or hormonal therapy? Will adjuvant ginseng use produce palliative effects in the breast cancer patient undergoing chemotherapy? To answer these questions, we will examine the effects of a wide dose-range of individual chemotherapy (doxorubicin, cyclophosphamide, paclitaxel) or hormonal (tamoxifen) therapy drugs, alone and in combinations with an extract of American ginseng, on the proliferation of human breast cancer cells (MCF-7, MDA-MB-231) in vitro. The results of this study will allow us to determine if adjuvant ginseng treatment alters the efficacy of standard cancer therapeutic drugs. From these results, we will determine the treatment regimens to be tested in vivo in female athymic nude mice inoculated with either MCF-7 or MDA-MB- 231 cells, monitoring tumor growth as well as general well-being and systemic toxicity. These preclinical studies will allow us to determine the potential palliative effects concomitant ginseng treatment may have in animals receiving the potent cancer therapeutic drugs. Thirdly, we will examine potential additive, synergistic or sub-additive effects of combination ginseng/chemotherapy treatment on pathway-specific genes/proteins involved in cell cycle regulation, apoptosis and cytotoxicity. Together, the results of these studies will provide us with a better understanding of American ginseng and will allow evidence-based decisions to be made by breast cancer patients and their physicians regarding complementary ginseng use during standard chemotherapy.

描述（由申请人提供）：人参是人类广泛用来治疗缺乏耐力，食欲不振和卡氏症以及阳ot的草药。在亚洲医学中，人参是用于治疗癌症（包括乳腺癌）的草药中的常见成分。最近有科学证据表明，人参及其人参糖苷成分有效地抑制体内乳腺癌细胞的增殖和肿瘤生长。因此，许多患者在使用标准化疗和荷尔蒙治疗方案治疗期间可能会服用人参补充剂，以增强治疗结果并改善癌症化学治疗药物的副作用。但是，没有关于辅助人参的使用如何影响癌症治疗药物的功效的信息。该R21提案将解决以下问题。人参的辅助使用会有助于或干扰标准的乳腺癌化学或激素治疗吗？辅助人参是否会在接受化学疗法的乳腺癌患者中产生姑息性作用？要回答这些问题，我们将单独研究单个化学疗法（阿霉素，环磷酰胺，紫杉醇）或激素（他莫昔芬）治疗药物的广泛剂量范围的影响，并与美国人参的提取物结合，对人类乳腺癌细胞的繁殖（MCF-7，MCF-7，MDA-MDA-MDA-MDA-MDA-MDA-231），INTRO。这项研究的结果将使我们能够确定辅助人参治疗是否改变了标准癌症治疗药物的疗效。从这些结果中，我们将确定在接种MCF-7或MDA-MB-231细胞的雌性裸鼠中要在体内测试的治疗方案，从而监测肿瘤的生长以及一般的幸福感和全身毒性。这些临床前研究将使我们能够确定在接受有效癌症治疗药物的动物中可能对人参治疗的潜在姑息作用。第三，我们将检查人参组合/化学疗法治疗对涉及细胞周期调节，凋亡和细胞毒性涉及的途径特异性基因/蛋白质的潜在添加剂，协同或亚添加作用。总之，这些研究的结果将使我们对美国人参有了更好的了解，并将允许乳腺癌患者及其医生在标准化疗期间对互补的人参使用做出基于证据的决定。